TAE Life Sciences Announces First Cancer Patient Treatments Using Accelerator-Based Biologically Targeted Radiation Therapy (BNCT)

4 years ago

Patients underwent BNCT using TAE Life Sciences’ Neutron Beam System as part of Neuboron Medical Group’s NeuPex System at Xiamen…

TAE Life Sciences Announces First Cancer Patient Treatments Using Accelerator-Based Biologically Targeted Radiation Therapy (BNCT)

4 years ago

Patients underwent BNCT using TAE Life Sciences’ Neutron Beam System as part of Neuboron Medical Group’s NeuPex System at Xiamen…

Anteris Announces Completion of A$35 Million Capital Raise and Provides 2023 Goalposts

4 years ago

Company Funded Through Results of U.S. Early Feasibility Study of DurAVR™ BRISBANE, Australia and EAGAN, Minn.--(BUSINESS WIRE)--Anteris Technologies Ltd (ASX:…

Anteris Announces Completion of A$35 Million Capital Raise and Provides 2023 Goalposts

4 years ago

Company Funded Through Results of U.S. Early Feasibility Study of DurAVR™ BRISBANE, Australia and EAGAN, Minn.--(BUSINESS WIRE)--Anteris Technologies Ltd (ASX:…

Anteris Announces Completion of A$35 Million Capital Raise and Provides 2023 Goalposts

4 years ago

Company Funded Through Results of U.S. Early Feasibility Study of DurAVR™ BRISBANE, Australia and EAGAN, Minn.--(BUSINESS WIRE)--Anteris Technologies Ltd (ASX:…

VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B

4 years ago

BI-2601 (BRII-179) and BRII-835 combination was generally well-tolerated with no new safety signals observed Initial data suggest VBI-2601 (BRII-179) and…

VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B

4 years ago

BI-2601 (BRII-179) and BRII-835 combination was generally well-tolerated with no new safety signals observed Initial data suggest VBI-2601 (BRII-179) and…

VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B

4 years ago

BI-2601 (BRII-179) and BRII-835 combination was generally well-tolerated with no new safety signals observed Initial data suggest VBI-2601 (BRII-179) and…

Asahi Kasei Completes Second Plant for Ceolus™ Microcrystalline Cellulose

4 years ago

NEW YORK & DÜSSELDORF, Germany & TOKYO--(BUSINESS WIRE)--#asahikasei--Asahi Kasei, a diversified Japanese multinational company, has completed the construction of its…

Asahi Kasei Completes Second Plant for Ceolus™ Microcrystalline Cellulose

4 years ago

NEW YORK & DÜSSELDORF, Germany & TOKYO--(BUSINESS WIRE)--#asahikasei--Asahi Kasei, a diversified Japanese multinational company, has completed the construction of its…